CRNX
Crinetics Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$84.95
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 42.2M | 7.7M | 1.0M | 4.0M | 4.7M |
| Cost of Revenue | 354.0K | 1.1M | — | — | — |
| Gross Profit | 41.8M | 6.6M | 1.0M | 4.0M | 4.7M |
| Operating Expenses | |||||
| R&D Expense | 375.4M | 332.1M | 240.2M | 168.5M | 130.2M |
| SG&A Expense | 214.4M | 191.3M | 99.7M | 58.1M | 42.4M |
| General & Admin Expense | 156.8M | 191.3M | 99.7M | 58.1M | 42.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.1M | — | — | — | — |
| Total Operating Expenses | 590.9M | 523.4M | 339.9M | 226.6M | 172.6M |
| Cost and Expenses | 591.2M | 524.5M | 339.9M | 226.6M | 172.6M |
| Operating Income (EBIT) | (549.1M) | (516.8M) | (338.9M) | (222.6M) | (167.9M) |
| Non-Operating | |||||
| Interest Income | 48.4M | 52.0M | 41.4M | 13.4M | 4.3M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 48.4M | 52.0M | 41.4M | 13.4M | 4.3M |
| Other Non-Op Income/Expense | 47.7M | 51.6M | 40.4M | 8.1M | 4.0M |
| Non-Operating Income (excl Interest) | (36.1M) | (51.6M) | (40.4M) | (8.1M) | (4.0M) |
| EBT (Pre-Tax Income) | (501.4M) | (465.1M) | (298.4M) | (214.5M) | (163.9M) |
| Income Tax Expense | 180.0K | 180.0K | — | — | — |
| Bottom Line | |||||
| Net Income | (501.6M) | (465.3M) | (298.4M) | (214.5M) | (163.9M) |
| Earnings from Cont. Ops | (501.6M) | (465.3M) | (298.4M) | (214.5M) | (163.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (501.6M) | (465.3M) | (298.4M) | (214.5M) | (163.9M) |
| Per Share | |||||
| Basic EPS | ($5.05) | ($4.95) | ($3.69) | ($3.69) | ($3.15) |
| Diluted EPS | ($5.05) | ($4.95) | ($3.69) | ($3.69) | ($3.15) |
| Revenue Per Share | $0.40 | $0.08 | $0.01 | $0.07 | $0.09 |
| Shares | |||||
| Basic Shares Outstanding | 105.6M | 94.1M | 80.8M | 58.1M | 52.0M |
| Diluted Shares Outstanding | 105.6M | 94.1M | 80.8M | 58.1M | 52.0M |
| Profitability Metrics | |||||
| EBITDA | (508.8M) | (461.2M) | (295.6M) | (213.4M) | (162.9M) |
| D&A | 4.2M | 3.9M | 2.8M | 1.1M | 983.0K |
| EBIT | (513.0M) | (465.1M) | (298.4M) | (214.5M) | (163.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026